Simultaneous nuclear and cytoplasmic expression of other members of the MAGE-A family including MAGE-A2 and MAGE-A3 in patients with prostate cancer revealed a significant correlation with clinic-pathological outcomes and recurrence-free survival13,63. This evidence concerns the gene MAGEA2 and prostate carcinoma.